PMDA drug package insert
メファキン「ヒサミツ」錠275
PMDA Prescription drug · 久光製薬株式会社 · package insert Dec 22, 2023
Key facts
| Brand names | メファキン「ヒサミツ」錠275 |
|---|---|
| Nonproprietary names | メフロキン塩酸塩 |
| Companies | 製造販売元／久光製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗マラリア剤 |
| Therapeutic category codes | 876419 |
| YJ codes | 6419003F1039 |
| Approval numbers | 21300AMY00125000 |
| Package insert edition | 第1版 |
| Package insert date | Dec 22, 2023 |
| PMDA document key | 650034_6419003F1039_1 |
| PMDA company code | 650034 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: